anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants will be administered fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG) chemotherapy on days -1 to 5 and gilteritinib will be administered once per day on days 8 to 21 at the assigned dose. Participants may receive prophylactic intrathecal cytarabine at the start of the cycle, as per institutional standards. A participant completing 2 cycles (cycle is defined as 28 days) will have the option to participate in long term treatment (LTT) with gilteritinib (for up to 2 years).
Systems and methods are described herein for estimating and filtering electrophysiological signals. In some examples, a noise filtering system can be employed to receive at least one electrophysiological signal. A signal segment extractor of the system can extract a signal segment of interest from the electrophysiological signal. The system employs a signal segment noise calculator to evaluate the extracted signal segment of interest to estimate a noise in the signal segment of interest. The estimated noise can be provided to a signal segment filter of the system to determine a surrogate noise estimate for at least one remaining signal segment of the electrophysiological signal for noise filtering the at least one remaining signal segment. The signal segment noise calculator can be configured to filter the signal segment of interest based on the estimated noise and the filtered signal segments can be combined to provide a filtered electrophysiological signal.
The present invention discloses water soluble heteropolysaccharides of a tuckahoe mycelium as spawn artificially cultured, a preparation method thereof and purposes thereof. The water soluble heteropolysaccharides have antineoplastic activity. A culture medium is prepared from corn steep liquor as a main ingredient, and the tuckahoe mycelium is cultured through the submerged fermentation of wild tuckahoe spawn; water soluble heteropolysaccharides are respectively extracted from the mycelium with physiological saline and hot water. The obtained heteropolysaccharides are mainly composed of alpha-D-glucose, mannose, galactoside and proteins. Activity experiment results in vivo indicate that the water soluble heteropolysaccharides perform obvious inhibiting action on the growth of an Sarcoma180 tumor implanted in a mouse in vivo and perform no toxic or side effect. Activity experiments results in vitro indicate that the water soluble heteropolysaccharides have a significant inhibiting effect on the proliferation of acute leukemia poison cells (HL-60) of a human body without destroying the proliferation of normal monkey kidney cells. The water soluble heteropolysaccharides can be used as antitumor medicines or as health products for improving the immunological function of organisms.
The difficulty of cochlear implantation in patients with congenital microtia is usually increased due to the vague anatomical marks and facial nerve malformation. The common types of facial nerve malformation include facial nerve bony cover loss, aberrant position, and bifurcation malformation. Bifurcation malformation may obscure the oval window, press against stapes, and bifurcate in the vestibular window while obscuring the round window. It is important to correctly identify the facial nerve and choose a reasonable surgical approach to avoid postoperative complications. This article describes a case of profound sensorineural hearing loss due to facial nerve malformation in our institution. The patient underwent cochlear implantation through the retro-facial approach. There was no facial nerve injury or dysfunction symptoms such as facial paralysis and hemifacial spasm 2 years after the operation, and the cochlear implant works well. The score of the categories of the auditory performance(CAP) questionnaire was 7, and the score of the speech intelligibility rating(SIR) questionnaire was 4. When the round window cannot be exposed through the facial recess approach during surgery, the retro-facial approach is a feasible method. To avoid facial nerve injury, a thin-section CT of the temporal bone should be performed before the middle and inner ear surgery for patients with facial nerve malformation, and the intraoperative facial nerve monitor should be used to clarify the course of the facial nerve to avoid injury.
BACKGROUND: Basic helix-loop-helix ARNT like 2 (ARNTL2) is a transcription factor that controls the circadian rhythm. Amounts of studies have demonstrated the carcinogenic function of ARNTL2 in human malignant tumors albeit the underlying mechanisms remain poorly understood. We aimed to study the significance of ARNTL2 in bladder cancer (BLCA).
METHODS: Immunohistochemical staining, immunoblotting and the database from TCGA were used to analyze the clinical relevance of ARNTL2, enolase 1 (ENO1) and solute carrier family 31 member 1 (SLC31A1) in BLCA. The function of ARNTL2 was explored by cell proliferation assay, apoptosis, colony formation and xenografted tumorigenesis. The molecular mechanisms of ARNTL2-driving BLCA development were investigated by RT-qPCR, immunoblotting and luciferase assays. Glycolysis was checked by measuring glucose consumption and lactate production. ENO1 activity was assessed by using indicated assay kit.
RESULTS: Overexpression of ARNTL2 facilitates the proliferation and tumorigenesis of BLCA cells through suppression of apoptosis and enhancement of glycolysis. Up-regulation of SLC31A1, ENO1, and enhancement of SLC31A1-mediated ENO1 activity were critical for ARNTL2-triggered glycolysis and malignant growth in BLCA cells. ARNTL2 was positively correlated with SLC31A1 and ENO1 in BLCA patients. High expression of ARNTL2, SLC31A1 or ENO1 predicted the poor prognosis of BLCA patients. Depletion of SLC31A1 and inhibition of glycolysis completely blunted the growth ability of BLCA cells.
CONCLUSION: In summary, ARNTL2 facilitates the progression of BLCA via activating ENO1-mediated glycolysis in a SLC31A1-independent and -dependent manner. Inhibiting SLC31A1 and glycolysis may be an aspirational approach for the treatment of BLCA patients with overexpression of ARNTL2.
In February 2015, Ueshima et al published an article regarding ultrasound guided transversus thoracic muscle plane (TTP) block for breast cancer resection. In this article, he showed that branches of the intercostal nerves (Th2-6) dominate the region of the internal mammary area. By administering local anesthetics between the internal intercostal and transversus thoracic muscle, analgesia in the anterior chest and sternum can be obtained. A cadaveric study shows injectate spread from the second to fifth intercostal spaces with a single 15mL injection between the third and fourth ribs next to the sternum. They further published a case series of two patients who successfully underwent median sternotomy for aortic valve replacement and thymoma resection using only the TTP block for analgesia. Fast- track cardiac surgery is now widely practiced, and evidence for its safety and efficacy has spurred its adoption. With the increased demand for health care resources including nursing manpower and ICU beds, postoperative patients are returning to the cardiac surgery intensive care unit (CSICU) on shorter acting anesthetic agents so that they can be awakened, following commands and spontaneously ventilating earlier. The TTP block fits in well with the fast- track paradigm. By providing adequate analgesia for median sternotomy, the TTP block may reduce narcotic requirements and consequent sedation and respiratory depression, hypercapnia and respiratory acidosis, prolonged mechanical ventilation and need for emergency advanced airway interventions.
The application discloses a management method, a management device and a storage medium of medical equipment. The management method comprises the steps of firstly obtaining and storing initial maintenance parameters of the medical equipment, then generating actual maintenance parameters, and adjusting the initial maintenance parameters when the actual maintenance parameters are different from the initial maintenance parameters. The initial maintenance parameter may be a factory value of the medical device, or may be a last adjusted maintenance parameter, which is an estimated value obtained according to the last stage of maintenance parameters. However, after a period of operation of the medical device, its usage may change. The method and the device generate the current actual maintenance parameters of the medical equipment according to the big data, and adjust the initial maintenance parameters when the actual maintenance parameters are different from the initial maintenance parameters, so that the maintenance parameters of the medical equipment are more consistent with the current use condition of the medical equipment. The medical equipment can not be returned to the factory for maintenance in advance, the maintenance frequency can be reduced, the maintenance cost can be reduced, the medical equipment can not be returned to the factory for maintenance in the future, and the failure rate can be reduced.
In hospitals, venous blood sampling as the first step in diagnosis and planning of medical treatment is among the most basic and common procedures all over the world. Before the diagnosis and treatment of acute or chronic health problems, venous blood is requested from the doctors and the blood sample is collected by the nurses. Patients experience anxiety for reasons such as the fear of experiencing pain during the blood donation process, fear of seeing blood and fear that blood-borne diseases will pass. Pain and anxiety because of invasive procedures lead to prolongation of the examination period and treatment procedures, and the rejection of treatment. Various distraction methods such as pharmacological local anesthetic creams, non-pharmacologically vibrating tourniquet, buzzy device, virtual reality have been used to reduce pain during invasive procedures. Vibrating tourniquet application during blood collection in pediatric patients was found to be effective on the pain felt. In another study conducted in pediatric patients, it was found that using a buzzy device, watching cartoons, and playing digital games during blood collection were effective in pain and fear management. Virtual reality is defined as "a technology that allows three-dimensional pictures and animations created in the computer environment to interact with these objects in the environment, which gives the feeling of being in a real environment in people's minds with technological tools". In the studies, virtual reality was applied in many studies during blood collection in pediatric patients. It was found that children who used virtual reality during invasive procedures in the pediatric nephrology clinic reported lower pain intensity and stress level compared to the control group. In the literature, research involving an attempt to reduce pain and anxiety during blood collection in adult patients has been found and studies involving attempts to reduce pain and anxiety during other invasive procedures are limited. In a study examining the pain and fear of adult outpatients during the treatment, it was found that the pain and anxiety levels of the virtual reality application group were low and they were highly satisfied with virtual reality. The aim of this research is to determine the effect of virtual reality on pain and anxiety during blood collection of patients who applied to the blood collection unit of a university hospital.
This is a multi-center study with a minimum of three clinical sites across diverse geographical areas in the United States. Approximately one-third of the total number of sites will have a patient population of low Neisseria gonorrhoeae (NG), Chlamydia trachomatis (CT), or Trichomonas vaginalis (TV) prevalence. Low prevalence sites are defined as sites with a prevalence \< / = 2 percent for any of the three targets. Sites with a prevalence higher than 2 percent for any of the three targets will be defined as high prevalence sites. The study will enroll approximately 1750 female subjects, 14 years of age and older, and will have a study duration of approximately 9 months after enrollment of the first subject. Female subjects seen at the participating sites for any reason will be evaluated for enrollment in this study. All subjects will be managed per standard of care as applicable. Subjects who are enrolled in the study will perform self-collection of a vaginal swab to be tested by Click device and allow the health care provider (HCP) to collect three additional vaginal swabs to be tested by recognized FDA-cleared comparator methods. Subjects will complete the study in a single visit, approximately 60 minutes in length. The hypothesis of this study is that Click Diagnostics Sexual Health Test performs substantially equivalent to the NAAT (Nucleic Acid Amplification Test) predicate system, and the identification of each organism (CT, NG, and TV) in self-collected vaginal swabs by women using the Click device will agree with the Patient Infected Status (PIS) with a high sensitivity and specificity. The primary objective is to assess the performance of the Click device for detection of CT, NG, and TV in self-collected vaginal specimens as compared to PIS determined by three approved comparator assays using vaginal specimens collected by a qualified HCP in support of obtaining FDA clearance and a Clinical Laboratory Improvement Amendments (CLIA) Waiver. The secondary objectives are: 1) to assess the performance of the Click device for detection of CT, NG, and TV in self-collected vaginal specimens among symptomatic subjects as compared to PIS determined by three approved comparator assays using vaginal specimens collected by a qualified HCP; 2) to assess the performance of the Click device for detection of CT, NG, and TV in self-collected vaginal specimens among asymptomatic subjects as compared to PIS determined by three approved comparator assays using vaginal specimens collected by a qualified HCP.
* Administer Teriparatide Injection as a subcutaneous injection into the thigh or abdominal region. Teriparatide Injection is not approved for intravenous or intramuscular use. 
  * Teriparatide Injection should be administered initially under circumstances in which the patient can sit or lie down if symptoms of orthostatic hypotension occur [see Warnings and Precautions (5.4)]. 
  * Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration (Teriparatide Injection is a clear and colorless liquid). Do not use if solid particles appear or if the solution is cloudy or colored. 
  * Patients and/or caregivers who administer Teriparatide Injection should receive appropriate training and instruction on the proper use of the Teriparatide Injection prefilled delivery device (pen) from a qualified health professional.
<P>PROBLEM TO BE SOLVED: To provide a liver-protecting agent obtained from Sedum sarmentosum Bge., a plant of the family Crassulaceae, medicines or foods for human or animals exhibiting a liver-protecting effect, and a new megastigmane compound prepared by separating and purifying extracted ingredients from Sedum sarmentosum Bge.  <P>SOLUTION: The liver-protecting agent comprises the entire plant of Sedum sarmentosum Bge., an extract liquid obtained by extraction from Sedum sarmentosum Bge. with water, a hydrous lower aliphatic alcohol or the like, an extract obtained by concentration of the extract liquid, or a megastigmane compound obtained by separating and purifying the extract liquid or the like. The medicine and foods for human or animals contain the liver-protecting agent. The novel megastigmane compound is obtained by separation and purification of the extract liquid or the like.  <P>COPYRIGHT: (C)2009,JPO&INPIT
All participants should be able to use a touchscreen, as this type of technology is used in the virtual e-biking training. Participants complete a questionnaire and subsequently engage in 12 weeks of home-based virtual e-biking training. A loaned bicycle will be provided for the training period and set up in the participants' own homes. Setup and adjustments will be performed by trained healthcare personnel. The following measurements will be taken before and after the training period: weight, height, hip-waist measurements, blood pressure, a 30-second sit-to-stand test, a timed-up-and-go test, ankle measurements, and a functional threshold power test (FTP). Seven accelerometers will be attached to the right and left arms, thighs, lower legs, and sternum using NJaP patches and worn for 72 hours at the beginning and end of the training period. The accelerometers can be easily removed after 72 hours.

The e-biking intervention consists of 3 sessions per week at the beginning of the study and gradually increases over the training period to 6 sessions per week, with three of these sessions being online and group-supervised.
TOP1288, a narrow spectrum protein kinase inhibitor, is being developed as a novel, non-absorbed treatment for ulcerative colitis (UC). UC is a disease of unknown cause characterised by inflammation of the lining of the large intestine and manifesting with abdominal pain and bloody diarrhoea. TOP1288 given rectally has a local anti-inflammatory action in experimental models of UC. The present study will be the first time TOP1288 has been given to humans and explores the safety, tolerability and how the body handles (absorbs, distributes and eliminates) TOP1288 and seeks evidence of the biochemical effect of the drug in the body. The study is in three parts: Part 1 investigates single doses in groups of healthy volunteers, each group dosed with an increased dose provided the drug was safe and well tolerated at the previous level. Part 2 investigates multiple ascending doses in healthy volunteers each group dosed with an increased dose provided the drug was safe and well tolerated at the previous level. Part 3 investigates one dose level by administering that dose in patient volunteers with UC. The study design is adaptive - that is after the first dose level in Part 1, which is predefined, the exact dose and dose-intervals can be modified from a pre-set plan by a Safety Review Committee in the light of the emerging results.
The invention relates to an anticancer medicine composition and applications of combined administration of the anticancer medicine composition and anticancer agents in treating cancers. The anticancer medicine composition contains alpha interferon or high-molecular polymer conjugates thereof. When the interferon alpha-conjugate as one of the high-molecular polymer conjugates is compared with existing alpha interferon, the half-life period of the interferon alpha-conjugate is prolonged in vivo, and the anticancer activity is better. Especially when the combined administration of the anticancer medicine composition and the anticancer agents of gemcitabine and the like is carried out, synergistic effects are shown in the aspect of inhibition of cancer cell increase and propagation, and therefore the anticancer medicine composition shows excellent anticancer activity. In addition, because that the half-life period and anticancer activity of the anticancer medicine composition are excellent, the administered frequency can be decreased remarkably. The combined administration of the interferon alpha-conjugate with excellent anticancer activity and anticancer agents can increase the dosage of anticancer agents, the side effects of anticancer agents can be lowered, and the compliance of patients to treatment can be raised.
Participants will receive standard of care NA treatment (Entecavir \[ETV\], Tenofovir Disoproxil Fumarate \[TDF\], Tenofovir Alafenamide \[TAF\]) in screening phase (up to 6 weeks) and in baseline visit (Day -1). NA treatment will be discontinued on Day 1 up to 96 weeks (Post-NA discontinuation off-treatment phase). Off-treatment refers to the phase after baseline, in which NA treatment will be discontinued.
Training will consist of six levels (A-F) with six inspirations at each level for up to 36 breaths per session. TIRE data will be stored in the tablet and automatically synced to account on cloud-based online platform for subsequent interrogation and data retrieval. Before every training session, subjects will be required to complete one maximal and sustained inspiratory effort from which the training is based on for that day.
BACKGROUND: Recent research indicates a positive correlation between DEP structural domain-containing 1B (DEPDC1B) and the cell cycle in various tumors. However, the role of DEPDC1B in the infiltration of the tumor immune microenvironment (TIME) remains unexplored.
METHODS: We analyzed the differential expression and prognostic significance of DEPDC1B in colon adenocarcinoma (COAD) using the R package "limma" and the Gene Expression Profiling Interactive Analysis (GEPIA) website. Gene set enrichment analysis (GSEA) was employed to investigate the functions and interactions of DEPDC1B expression in COAD. Cell Counting Kit-8 (CCK-8) assays and colony formation assays were utilized to assess the proliferative function of DEPDC1B. Correlations between DEPDC1B expression and tumor-infiltrating immune cells, immune checkpoints, tumor mutational burden (TMB), and microsatellite instability (MSI) status were examined using Spearman correlation analysis and CIBERSORT.
RESULTS: DEPDC1B was highly expressed in COAD. Elevated DEPDC1B expression was associated with lower epithelial-to-mesenchymal transition (EMT) and TNM stages, leading to a favorable prognosis. DEPDC1B mRNA was prominently expressed in COAD cell lines. CCK-8 and colony formation assays demonstrated that DEPDC1B inhibited the proliferation of COAD cells. Analysis using the CIBERSORT database and Spearman correlation revealed that DEPDC1B correlated with four types of tumor-infiltrating immune cells. Furthermore, high DEPDC1B expression was linked to the expression of PD-L1, CTLA4, SIGLEC15, PD-L2, TMB, and MSI-H. High DEPDC1B expression also indicated responsiveness to anti-PD-L1 immunotherapy.
CONCLUSIONS: DEPDC1B inhibits the proliferation of COAD cells and positively regulates the cell cycle, showing a positive correlation with CCNB1 and PBK expression. DEPDC1B expression in COAD is associated with tumor-infiltrating immune cells, immune checkpoints, TMB, and MSI-H in the tumor immune microenvironment. This suggests that DEPDC1B may serve as a novel prognostic marker and a potential target for immunotherapy in COAD.
Human Immunodeficiency virus causes depletion of CD4 cells. The depletion of CD4 cells results in decrease in immunity of an infected individual. Due to decrease immunity various opportunistic infections occur. These infections are cause for morbidity and mortality in HIV infected individuals. The treatment of HIV these includes antiretroviral drugs. These drugs have their own side effects and immune reconstitution achieved is delayed and slow. Various attempts have been made to improve CD4 count, use of IL-2 is one of them. It is associated with systemic side effects during the period of its administration. The present invention provides immunomodulator based on Mycobacterium w. Its use in associated with symptomatic improvement as well as improvement in immunity as evidenced by improved CD4 count in HIV infected individuals.